An outbreak of multi-drug resistant tuberculosis has been reported on Daru Island, Papua New 21 Guinea. The Mycobacterium tuberculosis strains driving this outbreak and the temporal accrual 22 of drug resistance mutations have not been described. We analyzed 100 isolates using whole 23 genome sequencing and found 95 belonged to a single modern Beijing strain cluster. Molecular 24 dating suggested acquisition of streptomycin and isoniazid resistance in the 1960s, with 25 virulence potentially enhanced by a mycP1 mutation. The outbreak cluster demonstrated a high 26 degree of co-resistance between isoniazid and ethionamide (80/95; 84.2%) attributed to an inhA 27 promoter mutation combined with inhA and ndh coding mutations. Multidrug resistance (MDR), 28 observed in 78/95 samples, emerged with the acquisition of a typical rpoB mutation together 29 with a compensatory rpoC mutation in the 1980s. There was independent acquisition of 30 fluoroquinolone and aminoglycoside resistance; with evidence of local transmission of 31 extensively-drug resistant (XDR) strains from 2009. These findings underscore the importance of 32 whole-genome sequencing in informing an effective public health response to MDR/XDR M. 33 tuberculosis. 34 35 36 Globally, an estimated 10.4 million cases of tuberculosis (TB) occurred in 2015 and 38 Mycobacterium tuberculosis was the leading single pathogen killer on the planet (1). The 39 emergence and spread of drug resistant M. tuberculosis strains pose a major challenge to global 40 TB control (2). Multi-drug resistant (MDR) TB, which is resistant to at least isoniazid and 41 rifampicin accounted for an estimated 480,000 new cases and 250, 000 deaths in 2015 (1). 42 Additional resistance to fluoroquinolones and second-line injectables defines extensively drug-43 resistant (XDR) TB (3). In M. tuberculosis, drug resistance occurs mainly due to the 44 accumulation of chromosomal resistance conferring mutations without evidence of lateral gene 45 transfer (4). The emergence of drug resistance is dependent on the rate of acquisition of 46 resistance conferring mutations and the frequency with which these drug resistant strains are 47 transmitted within the community (5, 6). Compensatory mutations that limit the fitness cost 48 imposed by drug resistance may enhance the clonal spread of the most successful drug resistant 49 strains (6-8).
Introduction
comment on the geographic spread of this outbreak cluster, but phylogenetic analysis combined 151 with detailed molecular dating suggests that it has been in local circulation since the 1940s and 152 first acquired drug resistance mutations in the 1960s. The identification of four different clades 153 with distinct evolutionary trajectories suggests a 'permissive' environment for the M. 154 tuberculosis strains to acquire and spread drug resistance within the study setting. 155 Clade C was the most successful clade, acquiring resistance to all four first line drugs and 156 demonstrating clonal spread of both MDR and XDR strains. Phylogenetic analysis indicated that 157 isoniazid and streptomycin resistance was acquired by strains ancestral to clades B, C and D. 158 This is consistent with the use of non-rifampicin containing regimens in the 1960s that were 159 highly reliant on isoniazid and streptomycin (22) . Similar analysis done in Russia and South 160 Africa where large MDR outbreaks have been recorded also indicated that streptomycin and 161 isoniazid resistance were acquired before the introduction of rifampicin containing regimens.
162
These settings mostly reported high-level isoniazid resistance due to katG mutations (6, 12) . In a 163 recent multinational study, katG (p.Ser315Thr) was identified as the harbinger mutation that is 164 most frequently associated with future MDR occurrence and risks subsequent clonal spread (23).
166
Contrary to the experience in most other settings, (23, 24) The selective advantage of clade C would have been enhanced by the acquisition of a classic 180 rpoB (p.Ser450Leu) rifampicin resistance determining mutation together with a compensatory 181 rpoC (p.Val483Gly) mutation that would have abrogated its negative fitness effects (7) . Similar 182 to previous observations, (28) one strain had two rpoB mutations of which p.Ile480Val, which 183 lies outside the 81bp rifampicin resistance determining region, may represent a compensatory 184 mutation. The single strain within the clade D rpoB (p.Ser450Leu) cluster, in which we were 185 unable to detect an rpoB mutation, may have been from a heteroresistant population since the 186 same rpoB mutation was detected in all the neighboring strains. Cultivation of the clinical 187 specimens probably favored selection of the observed strain (29).
188
An effective host immune response is critical to protect individuals against tuberculosis and to 189 limit ongoing transmission within communities. We identified a non-synonymous mycp1 190 (p.Thr238Ala) mutation that is ancestral to clades B, C and D. Mouse models used to identify M. progressive increase in the critical concentration (37). We could not identify any of the accompanying mutations previously identified, but hypothesize that a reduction in the critical using the international database (SpolDB4) (44). Paired end reads were quality checked using score<30) especially at 3' ends. Trimmed reads were mapped to the H37Rv reference genome 289 (GeneBank: NC_000962·3) using BWA-mem with default settings (47). The mean reference 290 coverage was 98·4% (range 96·4-99·8%) and mean high quality base coverage was 70·7X 291 (range 25-182X).
292
GATK UnifiedGenotyper was used to call SNPs and small indels (48). SNPs and small indels 293 with at least 10X read depth, 80% allele frequency and with at least 10bp difference between 294 neighboring SNPs/indels were retained using customized java and perl scripts. Indels of greater 295 than 4 mutations were excluded from the analysis unless occurring within a known drug 296 resistance associated gene. High quality SNPs and indels were annotated using SnpEff v4·1 (49) 297 and those in repetitive regions such as PE/PPE were excluded from analysis. The SNP allele 298 frequency spectrum was constructed to illustrate the allelic diversity ( Figure S1 ). We 299 characterized mutations in known genes (including regulatory mutations) that confer resistance 300 to rifampicin, isoniazid, ethambutol, streptomycin, pyrazinamide, fluoroquinolones, amikacin, 301 capreomycin, kanamycin, ethionamide, para-aminosalicyclic acid, cycloserine, bedaquiline, 302 linezolid and delamanid according to a literature review ( 
